iLet Bionic Pancreas Integrates With Eversense 365

Senseonics and Beta Bionics launch a combined automated insulin delivery and continuous glucose monitoring system in the United States.

Updated on Nov. 18, 2026 in Diabetes

iLet Bionic Pancreas Integrates With Eversense 365

Senseonics Holdings and Beta Bionics launched the iLet Bionic Pancreas integrated with the Eversense 365 continuous glucose monitoring system. The integration pairs a year-long implantable sensor with an automated insulin delivery system that requires no carb counting or manual correction boluses.

Why it matters

The launch links two automated diabetes technologies, offering users a combined system that determines and delivers insulin doses without manual input. For people with diabetes in the United States, it expands the range of options available for managing glucose levels with less daily effort.

Senseonics reported $19.6 million in third-quarter 2026 revenue, up 140% from $8.1 million a year earlier, according to company figures. Clinical outcome data for the combined system has not been reported in the source material.

The players

Senseonics Holdings

Senseonics Holdings is a medical technology company that develops the Eversense continuous glucose monitoring system, an implantable sensor designed for long-term use.

Beta Bionics

Beta Bionics is a medical device company that developed the iLet Bionic Pancreas, an automated insulin delivery system that received FDA clearance for its adaptive dosing algorithm.

The details

The iLet system uses a proprietary algorithm that learns and adapts to individual insulin needs over time, and users do not need to count carbohydrates or deliver manual correction doses. Eversense 365 delivers glucose readings with fewer sensor changes and fewer disruptive false alerts than traditional continuous glucose monitors.

Timeline

  1. June 2026: Senseonics announced a partnership with Welldoc to develop a next-generation app for Eversense 365.

  2. September 2026: Senseonics and Beta Bionics announced their partnership.

  3. October 2026: Senseonics announced an in-human study for Freedom, an investigational CGM system.

  4. November 16, 2026: The iLet integrated with Eversense 365 launched commercially.

Health Landscape

The integration builds on Beta Bionics' adaptive closed-loop insulin dosing algorithm, the first of its kind to receive FDA clearance. It extends that automated approach by combining it with a sensor that lasts a full year.

For eligible users aged 6 and older for iLet and 18 and older for Eversense 365, the integrated system removes the need for carb counting and manual correction doses. The sensor's year-long duration means fewer sensor changes than traditional monitors require.

The takeaway

Automated insulin delivery paired with longer-lasting glucose sensors can reduce the daily manual steps involved in diabetes management. Anyone considering these systems should discuss eligibility and fit with their own clinician.

What happens next

Senseonics plans to integrate Eversense 365 with Beta Bionics' Mint tubeless patch pump in the future, with no launch date given.

Further reading

Explore more on Diabetes to see how automated insulin delivery and glucose monitoring fit into current care options.